The m6A methyltransferase METTL3 modifies PGC-1α mRNA promoting mitochondrial dysfunction and oxLDL-induced inflammation in monocytes

Mitochondrial biogenesis and energy metabolism are essential for regulating the inflammatory state of monocytes. This state is partially controlled by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a coactivator that regulates mitochondrial biogenesis and energy metabolism. Disruption of these processes can also contribute to the initiation of chronic inflammatory diseases, such as pulmonary fibrosis, atherosclerosis, and rheumatoid arthritis. Methyltransferase-like 3 (METTL3)-dependent N6-methyladenosine (m6A) methylation has recently been shown to regulate a variety of inflammatory processes. However, the role of m6A mRNA methylation in affecting mitochondrial metabolism in monocytes under inflammation is unclear, nor is there an established relationship between m6A methylation and PGC-1α. In this study, we identified a novel mechanism by which METTL3 acts during oxidized low-density lipoprotein (oxLDL)-induced monocyte inflammation, where METTL3 and YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) cooperatively modify PGC-1α mRNA, mediating its degradation, decreasing PGC-1α protein levels, and thereby enhancing the inflammatory response. METTL3 coordinated with YTHDF2 to suppress the expression of PGC-1α, as well as that of cytochrome c (CYCS) and NADH:ubiquinone oxidoreductase subunit C2 (NDUFC2) and reduced ATP production and oxygen consumption rate (OCR). This subsequently increased the accumulation of cellular and mitochondrial reactive oxygen species (ROS) and the levels of proinflammatory cytokines in inflammatory monocytes. These data may provide new insights into the role of METTL3-dependent m6A modification of PGC-1α mRNA in the monocyte inflammation response. These data also contribute to a more comprehensive understanding of the pathogenesis of monocyte-macrophage inflammation-associated diseases, such as pulmonary fibrosis, atherosclerosis, and rheumatoid arthritis. Mitochondrial biogenesis and energy metabolism are essential for regulating the inflammatory state of monocytes. This state is partially controlled by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a coactivator that regulates mitochondrial biogenesis and energy metabolism. Disruption of these processes can also contribute to the initiation of chronic inflammatory diseases, such as pulmonary fibrosis, atherosclerosis, and rheumatoid arthritis. Methyltransferase-like 3 (METTL3)-dependent N6-methyladenosine (m6A) methylation has recently been shown to regulate a variety of inflammatory processes. However, the role of m6A mRNA methylation in affecting mitochondrial metabolism in monocytes under inflammation is unclear, nor is there an established relationship between m6A methylation and PGC-1α. In this study, we identified a novel mechanism by which METTL3 acts during oxidized low-density lipoprotein (oxLDL)-induced monocyte inflammation, where METTL3 and YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) cooperatively modify PGC-1α mRNA, mediating its degradation, decreasing PGC-1α protein levels, and thereby enhancing the inflammatory response. METTL3 coordinated with YTHDF2 to suppress the expression of PGC-1α, as well as that of cytochrome c (CYCS) and NADH:ubiquinone oxidoreductase subunit C2 (NDUFC2) and reduced ATP production and oxygen consumption rate (OCR). This subsequently increased the accumulation of cellular and mitochondrial reactive oxygen species (ROS) and the levels of proinflammatory cytokines in inflammatory monocytes. These data may provide new insights into the role of METTL3-dependent m6A modification of PGC-1α mRNA in the monocyte inflammation response. These data also contribute to a more comprehensive understanding of the pathogenesis of monocyte-macrophage inflammation-associated diseases, such as pulmonary fibrosis, atherosclerosis, and rheumatoid arthritis. Monocytes play an important role in the innate immune system and exhibit phagocytic activity to resist viral, bacterial, and fungal infections (1Shi C. Pamer E.G. Monocyte recruitment during infection and inflammation.Nat. Rev. Immunol. 2011; 11: 762-774Crossref PubMed Scopus (1603) Google Scholar, 2Auffray C. Sieweke M.H. Geissmann F. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells.Annu. Rev. Immunol. 2009; 27: 669-692Crossref PubMed Scopus (1104) Google Scholar). Circulating monocytes leave the bloodstream and migrate to inflamed tissues, where they can differentiate into macrophages or dendritic cells following stimulation by interaction with cytokines and/or microbial molecules (e.g., complement proteins, bacterial flagellin, lipopolysaccharide) (2Auffray C. Sieweke M.H. Geissmann F. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells.Annu. Rev. Immunol. 2009; 27: 669-692Crossref PubMed Scopus (1104) Google Scholar). Recruitment of monocytes is essential for effective control and clearance of pathogen infections, but persistent monocyte infiltration also contributes to the pathogenesis of chronic inflammatory and degenerative diseases, such as glomerulonephritis, pulmonary fibrosis, atherosclerosis, rheumatoid arthritis, and Alzheimer's disease (3Duffield J.S. Macrophages and immunologic inflammation of the kidney.Semin. Nephrol. 2010; 30: 234-254Abstract Full Text Full Text PDF PubMed Scopus (157) Google Scholar, 4Misharin A.V. Morales-Nebreda L. Reyfman P.A. Cuda C.M. Walter J.M. McQuattie-Pimentel A.C. Chen C.-I. Anekalla K.R. Joshi N. Williams K.J.N. Abdala-Valencia H. Yacoub T.J. Chi M. Chiu S. Gonzalez-Gonzalez F.J. et al.Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.J. Exp. Med. 2017; 214: 2387-2404Crossref PubMed Scopus (382) Google Scholar, 5Woollard K.J. Geissmann F. Monocytes in atherosclerosis: Subsets and functions.Nat. Rev. Cardiol. 2010; 7: 77-86Crossref PubMed Scopus (595) Google Scholar, 6Katschke K.J. Rottman J.B. Ruth